| Literature DB >> 31484499 |
Daria Antipova1, Leila Eadie2, Ashish Macaden3, Philip Wilson2.
Abstract
INTRODUCTION: Recanalisation therapy in acute ischaemic stroke is highly time-sensitive, and requires early identification of eligible patients to ensure better outcomes. Thus, a number of clinical assessment tools have been developed and this review examines their diagnostic capabilities.Entities:
Keywords: Acute cerebral ischaemia; Clinical prediction rules; Emergency care; Intracerebral haemorrhage; Large vessel occlusion; Recanalization; Scoring methods; Stroke; Thrombectomy; Thrombolysis
Mesh:
Year: 2019 PMID: 31484499 PMCID: PMC6727516 DOI: 10.1186/s12873-019-0262-1
Source DB: PubMed Journal: BMC Emerg Med ISSN: 1471-227X
Review inclusion and exclusion criteria
| Domain | Inclusion | Exclusion |
|---|---|---|
| Study type | Comparative observational studies | Case reports |
| Prospective observational studies | Selected case series | |
| Cohort studies | Literature review | |
| Unselected case series | Conference proceedings | |
| Full text unavailable | ||
| Participants | Human | Non-human subjects |
| Adults | Exclusively paediatric patients Mixed paediatric and adult populations (where paediatric and adult groups are not possible to identify separately) | |
| Patients with ischaemic stroke (including patients with LVO), acute haemorrhagic stroke, and/or stroke-mimicking conditions and transient ischaemic attack | Exclusively patients with non-stroke conditions, such as sickle cell disease, arteriovenous malformation, traumatic brain injury, cerebral tumour, subarachnoid haemorrhage, vertigo etc. | |
| Sample size ≥300 participants [ | Sample size < 300 participants | |
| Setting | Prehospital and in-hospital | |
| Procedure | Use of a clinical assessment tool, including clinical scales, individual symptoms and signs designed for identification of patients with ischaemic stroke, including subjects with LVO, acute haemorrhagic stroke, and/or stroke-mimicking conditions | Exclusively assessing the diagnostic accuracy of a brain imaging modality for identification of patients with acute stroke and/or stroke-mimicking conditions |
| Aims/outcomes | Diagnostic accuracy of clinical tools designed for identification of patients with ischaemic stroke, including subjects with LVO, acute haemorrhagic stroke, and/or stroke mimicking conditions | Exclusively assessing the prognosis of functional disability caused by a stroke |
| Diagnostic accuracy of clinical tools designed for differentiation between two main subtypes of stroke – ischaemic and haemorrhagic | Exclusively evaluating factors associated with misdiagnosis of stroke | |
| Exclusively diagnosing stroke patients with no assessment of clinical factors | ||
| Publication | 2015–2018 | Before January 2015 |
| In English | In languages other than English | |
Fig. 1PRISMA flowchart. Outline of the study selection process using inclusion and exclusion criteria
Diagnostic accuracy values of clinical tools for selecting subjects with large vessel occlusion
| Clinical assessment | Se | Sp | PPV | NPV | AUC |
|---|---|---|---|---|---|
| ACT-FAST [ | 0.85 | 0.93 | 0.53 | 0.99 | 0.90 |
| aNIHSS ≥1 [ | 0.95 | 0.31 | 0.40 | 0.92 | – |
| a-NIHSS item profile A ≥ 3 [ | 0.64 | 0.69 | 0.76 | 0.55 | 0.66 |
| a-NIHSS item profile B ≥ 2 [ | 0.75 | 0.64 | 0.76 | 0.63 | 0.71 |
| a-NIHSS item profile C ≥ 2 [ | 0.51 | 0.73 | 0.75 | 0.50 | 0.60 |
| a-NIHSS item profile D ≥ 2 [ | 0.76 | 0.61 | 0.75 | 0.62 | 0.70 |
| a-NIHSS item profile E ≥ 2 [ | 0.71 | 0.65 | 0.76 | 0.60 | 0.68 |
Aphasia; Neglect/gaze deviation [ | 0.91 | 0.70 | 0.60 | 0.94 | 0.77 |
| Arm weakness [ | 0.96 | 0.41 | 0.18 | 0.99 | 0.68 |
Arm weakness; Leg weakness; Dysarthria [ | 0.92 | 0.44 | 0.28 | 0.96 | – |
| Bernese score 1 ≥ 5 [ | 0.73 | 0.79 | 0.85 | 0.66 | 0.76 |
| Bernese score 2 ≥ 2 [ | 0.71 | 0.80 | 0.84 | 0.64 | 0.74 |
| Bernese score 3 ≥ 2 [ | 0.67 | 0.86 | 0.88 | 0.63 | 0.75 |
| Bernese score 4 ≥ 1 [ | 0.67 | 0.83 | 0.86 | 0.63 | 0.74 |
| Bernese score 5 ≥ 3 [ | 0.77 | 0.83 | 0.87 | 0.70 | 0.79 |
| CPSS ≥1 [ | 0.96 | 0.24 | 0.38 | 0.93 | – |
| CPSS ≥2 [ | 0.56–0.92 | 0.81–0.85 | 0.40–0.65 | 0.78–0.99 | 0.75–0.78 |
| CPSS1 ≥ 2 [ | 0.59 | 0.77 | 0.80 | 0.55 | 0.66 |
| CPSS2 ≥ 2 [ | 0.73 | 0.71 | 0.79 | 0.63 | 0.72 |
| CPSSS ≥1 [ | 0.60–0.86 | 0.80–0.87 | 0.88 | 0.59 | 0.71 |
| CPSSS ≥2 [ | 0.59–0.83 | 0.40–0.89 | 0.66–0.77 | 0.77–0.83 | 0.72–0.80 |
| CPSSS ≥3 [ | 0.51 | 0.93 | – | – | – |
| CPSSS =4 [ | 0.25 | 0.96 | – | – | – |
| C-STAT [ | 0.54 | 0.91 | 0.45 | 0.93 | 0.79 |
| C-STAT ≥2 [ | 0.47–0.85 | 0.68–0.85 | 0.35–0.40 | 0.88–0.98 | 0.65–0.85 |
| DIRECT criteria [ | 0.74 | 0.92 | 0.43 | 0.98 | 0.91 |
| EMSA ≥3 [ | 0.75 | 0.50 | – | – | 0.69 |
| Expressive aphasia [ | 0.39 | 0.64 | 0.13 | 0.88 | 0.52 |
| Facial weakness [ | 0.93 | 0.50 | 0.20 | 0.98 | 0.72 |
| FAST = 3 [ | 0.84 | 0.44 | 0.32 | 0.90 | 0.53 |
| FAST-ED [ | 0.62 | 0.84 | 0.40 | 0.94 | 0.84 |
| FAST-ED ≥3 [ | 0.71 | 0.78 | 0.62 | 0.84 | 0.76 |
| FAST-ED ≥4 [ | 0.42–0.96 | 0.82–0.90 | 0.24–0.80 | 0.82–1.00 | 0.64–0.91 |
| FPSS [ | 0.54 | 0.91 | 0.47 | 0.93 | 0.85 |
| Gaze deviation [ | 0.84 | 0.73 | 0.30 | 0.97 | 0.79 |
| G-FAST ≥3 [ | 0.75–0.89 | 0.39–0.83 | 0.31–0.39 | 0.92–0.96 | 0.51–0.85 |
| G-FAST =4 [ | 0.36 | 0.97 | 0.59 | 0.91 | |
| LAMS ≥4 [ | 0.57–0.94 | 0.74–0.85 | 0.28–0.66 | 0.78–0.99 | 0.70–0.89 |
| mNIHSS ≥5 [ | 0.78 | 0.76 | 0.85 | 0.69 | 0.78 |
| mNIHSS ≥7 [ | 0.77 | 0.77 | 0.62 | 0.87 | – |
| MPSS ≥3 [ | 0.84 | 0.65 | 0.54 | 0.89 | – |
| Neglect [ | 0.88 | 0.69 | 0.28 | 0.98 | 0.79 |
| Neglect/gaze deviation [ | 0.95 | 0.64 | 0.27 | 0.99 | 0.79 |
| NIHSS ≥4 [ | 0.93–0.99 | 0.24–0.46 | 0.15–0.46 | 0.93–0.99 | 0.62 |
| NIHSS ≥5 [ | 0.90 | 0.54 | 0.49 | 0.92 | – |
| NIHSS ≥6 [ | 0.66–0.99 | 0.39–0.70 | 0.18–0.55 | 0.85–1.00 | 0.68–0.72 |
| NIHSS ≥7 [ | 0.81 | 0.72–0.77 | 0.59–0.84 | 0.72–0.89 | 0.79 |
| NIHSS ≥8 [ | 0.72–0.98 | 0.48–0.81 | 0.21–0.71 | 0.82–0.99 | 0.71 |
| NIHSS ≥9 [ | 0.53–0.81 | 0.72–0.85 | 0.59–0.75 | 0.81–0.89 | – |
| NIHSS ≥10 [ | 0.64–0.98 | 0.56–0.88 | 0.23–0.78 | 0.80–0.99 | 0.75–0.84 |
| NIHSS ≥14 [ | 0.61 | 0.88 | 0.72 | 0.82 | – |
| NIHSS-8 [ | 0.63 | 0.89 | 0.44 | 0.94 | 0.84 |
| NIHSS-8 ≥ 8 [ | 0.81 | 0.75 | 0.52 | 0.92 | 0.82 |
| NIHSS subitem – LoC (1a) [ | 0.23 | 0.81 | 0.14 | 0.88 | 0.52 |
| NIHSS subitem – LoC (1b) [ | 0.60 | 0.56 | 0.16 | 0.91 | 0.58 |
| NIHSS subitem – LoC (1c) [ | 0.49 | 0.68 | 0.17 | 0.91 | 0.59 |
NIHSS; Absence of prestroke handicap (mRS ≤ 2); Hemineglect; AF; Female sex; Total score cut-off ≥16 [ | 0.84 | 0.68–0.71 | 0.41–0.54 | 0.92–0.94 | 0.84 |
| NIHSS symptom profile A or B [ | 0.76 | 0.65 | 0.40 | 0.90 | 0.68 |
| OoH-NIHSS ≥1 [ | 0.96 | 0.24 | 0.38 | 0.93 | – |
| PASS [ | 0.69 | 0.85 | 0.40 | 0.95 | 0.81 |
| PASS ≥2 [ | 0.64–0.96 | 0.59–0.84 | 0.33–0.74 | 0.81–1.00 | 0.63–0.89 |
| Pomona ≥1 [ | 0.98 | 0.50 | 0.21 | 0.99 | 0.74 |
| Pomona ≥2 [ | 0.86 | 0.71 | 0.71 | 0.97 | 0.79 |
| RACE ≥3 [ | 0.74 | 0.80 | 0.85 | 0.67 | 0.77 |
| RACE ≥5 [ | 0.46–0.92 | 0.68–0.91 | 0.27–0.81 | 0.78–0.99 | 0.67–0.90 |
| RACE V1 ≥ 4 [ | 0.85 | 0.56 | – | – | 0.81 |
| RACE V2 ≥ 4 [ | 0.85 | 0.62 | – | – | 0.79 |
| RACE V3 ≥ 3 [ | 0.89 | 0.48 | – | – | 0.78 |
| RACE V4 ≥ 4 [ | 0.87 | 0.56 | – | – | 0.80 |
| RACE V5 ≥ 4 [ | 0.83 | 0.57 | – | – | 0.79 |
| RACE V6 ≥ 4 [ | 0.83 | 0.63 | – | – | 0.77 |
| RACE V7 ≥ 3 [ | 0.87 | 0.51 | – | – | 0.76 |
Reduced level of consciousness with inability to answer questions; Leg weakness; Dysarthria; Gaze deviation [ | 0.96 | 0.39 | 0.27 | 0.98 | – |
Reduced level of consciousness with inability to answer questions; Facial weakness; Arm weakness; Sensation loss; Aphasia [ | 0.99 | 0.28 | 0.99 | 0.25 | – |
Reduced level of consciousness with inability to answer questions; Leg weakness; Neglect; Gaze deviation [ | 0.85 | 0.45 | 0.26 | 0.93 | – |
| rNIHSS (profile A, B, C, D or E vs. profile F) [ | 0.83 | 0.61 | 0.51 | 0.88 | – |
| ROSIER ≥4 [ | 0.79 | 0.76 | 0.61 | 0.88 | – |
| sCPSSS (severe arm weakness, conjugate gaze deviation) ≥1 [ | 0.83 | 0.83 | |||
| sCPSSS ≥2 [ | 0.59 | 0.90 | |||
| sCPSSS =3 [ | 0.50 | 0.94 | |||
| sNIHSS-1 ≥ 1 [ | 0.63 | 0.80 | 0.83 | 0.59 | 0.70 |
| sNIHSS-1 ≥ 2 [ | 0.66 | 0.81 | 0.63 | 0.83 | |
| sNIHSS-5 ≥ 2 [ | 0.76 | 0.77 | 0.84 | 0.68 | 0.76 |
| sNIHSS-5 ≥ 3 [ | 0.69 | 0.81 | 0.70 | 0.80 | 0.80 |
| sNIHSS-5 ≥ 4 [ | 0.72 | 0.80 | 0.63 | 0.85 | – |
| sNIHSS-8 ≥ 4 [ | 0.78 | 0.76 | 0.84 | 0.69 | 0.77 |
| sNIHSS-8 ≥ 6 [ | 0.64–0.77 | 0.78–0.88 | 0.63–0.78 | 0.79–0.88 | 0.82 |
| sNIHSS-EMS ≥6 [ | 0.70 | 0.81 | 0.70 | 0.81 | 0.81 |
| VAN [ | 0.95 | 0.56 | 0.23 | 0.99 | 0.77 |
| Visual field defect [ | 0.88 | 0.75 | 0.33 | 0.98 | 0.82 |
| 3I-SS [ | 0.42–0.50 | 0.92–0.93 | 0.45–0.77 | 0.77–0.92 | 0.71–0.78 |
| 3I-SS ≥1 [ | 0.73 | 0.78 | 0.83 | 0.65 | 0.75 |
| 3I-SS ≥2 [ | 0.65 | 0.72 | 0.42 | 0.87 | 0.71 |
| 3I-SS ≥4 [ | 0.19–0.40 | 0.94–0.95 | 0.74–0.85 | 0.71–0.74 | 0.65–0.80 |
Abbreviations: AUC area under the curve, NPV negative predictive value, PPV positive predictive value, Se sensitivity, Sp specificity
Fig. 2Bar chart. Sensitivity and specificity values across the clinical tools for selecting subjects with large vessel occlusion
Fig. 3Bar chart. Sensitivity and specificity values of clinical tools for differentiating between acute stroke and stroke-mimicking conditions
Diagnostic accuracy values of clinical tools for selecting subjects with acute stroke and stroke-mimicking conditions
| Clinical tool | Target condition | Se | Sp | PPV | NPV | AUC |
|---|---|---|---|---|---|---|
| CPSS [ | Acute stroke | 0.83 | 0.69 | 0.50 | 0.91 | – |
| FABS≥3 [ | Stroke mimic | 0.90 | 0.91 | 0.87 | 0.93 |
|
| FAST [ | Acute stroke | 0.76–0.85 | 0.64–0.68 | 0.50–0.93 | 0.30–0.92 | 0.70 |
| GZSS≥1.5 [ | Acute stroke | 0.83 | 0.74 | 0.95 | 0.42 | 0.87 |
| LAPSS [ | Acute stroke | 0.56 | 0.88 | 0.97 | 0.25 | – |
| LAPSS 1998 [ | Acute stroke | 0.44 | 0.98 | 0.87 | 0.82 | – |
| LAPSS 2000 [ | Acute stroke | 0.49 | 0.97 | 0.87 | 0.84 | – |
| MASS [ | Acute stroke | 0.63 | 0.94 | 0.79 | 0.87 | – |
| Med PACS [ | Acute stroke | 0.71 | 0.92 | 0.76 | 0.90 | – |
| MPDS [ | Acute stroke | 0.86 | 0.27 | 0.20 | 0.90 |
|
| ROSIER [ | Acute stroke | 0.78–0.80 | 0.71–0.79 | 0.59–0.94 | 0.34–0.91 | 0.77 |
| sNIHSS-EMS [ | Acute stroke | 0.91 | 0.52 | 0.43 | 0.93 | – |
| TriAGe+ ≥ 10 [ | Acute stroke | 0.78 | 0.72 | 0.57 | 0.87 | 0.78 |
Abbreviations: AUC area under the curve, NPV negative predictive value, PPV positive predictive value, Se sensitivity, Sp specificity